AbCellera’s antibody discovery engine will isolate novel antibodies
for the development of targeted CAR-T cell therapy
VANCOUVER, British Columbia–(BUSINESS WIRE)–#antibodies—AbCellera
announced today its collaboration with Autolus Therapeutics plc
(Autolus), a clinical stage biopharmaceutical company developing
next-generation programmed T cell therapies. Under the partnership,
AbCellera is applying its microfluidic single-cell screening platform to
find novel antibodies which can be used for the development of new
Chimeric Antigen Receptor (CAR) T cell therapies.
CARs are engineered targeting molecules comprised of a tumour-specific
antibody linked to a T cell activating receptor. T cells engineered to
express CARs (CAR-T cells) are capable of mounting specific and highly
effective immune responses against tumours; the approach shows great
promise, as exemplified by the recent approvals of CAR-T cell therapies
for the treatment of refractory (or relapsed) B cell leukemia. Because
of the high potency of CAR-T cells, their development into successful
therapies hinges on the use of highly specific antibody molecules that
can target T cells to the tumour while leaving other cells unaffected.
“CAR-T cell therapy is a breakthrough technology in the treatment of
cancer. It is already saving the lives of patients and there is
tremendous potential to expand its application broadly across blood
cancers and solid tumours. We are excited to be partnering with Autolus,
a leader in the development of programmed T cell therapies, to help turn
this potential into a reality,” commented Carl Hansen, CEO of AbCellera.
AbCellera’s technology enables deep mining of natural immune responses
by combining microfluidic single-cell screening and proprietary
repertoire sequencing technology with artificial intelligence.
AbCellera’s team uses expertise in animal immunizations for any species
(including humanized rodent platforms), assay design, bioinformatic
analysis and visualization tools, and antibody characterization for
function and developability to customize antibody discovery for every
project. This approach has proven powerful at unlocking previously
inaccessible targets, including complex membrane proteins, for a wide
range of therapeutic modalities.
“We are delighted to work with AbCellera on the identification of new
targeting domains for the development of potential new CAR-T cell
therapies,” said Dr. Christian Itin, chairman and chief executive
officer of Autolus.
About AbCellera Biologics Inc.AbCellera is a privately held
company that engages in partnerships to discover and develop
next-generation therapeutic antibodies. AbCellera’s single-cell platform
integrates end-to-end capabilities for therapeutic antibody discovery
through a unique combination of technologies including proprietary
immunizations, microfluidics, high-throughput imaging, genomics, deep
computation, artificial intelligence, and laboratory automation.
Ultra-deep screening of single B cells allows unprecedented access to
natural immune responses, enabling rapid isolation of large and diverse
panels of high-quality lead antibodies from any species, including
About AutolusAutolus is a clinical-stage biopharmaceutical
company developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular T
cell programming technologies, the company is engineering precisely
targeted, controlled and highly active T cell therapies that are
designed to better recognize cancer cells, break down their defense
mechanisms and eliminate these cells. Autolus has a pipeline of product
candidates in development for the treatment of hematological
malignancies and solid tumors.
Kevin Heyries, PhDTelephone: 604.559.9005Email: [email protected]